Guest Recognition with Micelle-Bound Cavitands
A R T I C L E S
reports for the synthesis of the C11-footed cavitand.24,25 Ethyl-footed
octanitro cavitand38 (300 mg, 0.24 mmol) was dissolved in DMF (12
mL) under N2. SnCl2·2H2O (1.5 g, 6.6 mmol) was added followed by
concentrated hydrochloric acid (6 mL). The reaction was heated to
105 °C for 16 h, cooled, and poured into iced water (75 mL). The
slurry was centrifuged, and the supernatant was decanted. The solid
was taken up in a minimal amount of methanol:CH2Cl2 and then
concentrated to remove excess water and DMF. The solid was treated
with 50 mL of dichloromethane, sonicated, filtered, and dried under
(PC) micelles and fold into the C4V vase conformation, serving
as small molecule hosts while residing in lipid micelles. As a
micelle-bound host, 1 has the ability to sequester hydrophobic
guests into its interior even though both host and guest are
submersed in a formidable sea of competing alkyl side chains.
The cavitands exhibit guest selectivity, which allowed us through
the use of a hydrophobic anchor to localize both a fluorophore
(2) and a dipeptide (3) within the micelle-bound receptor.
Subsequent exploration of other cavitand substitution patterns
reveals some flexibility and tolerance in both substitution at
the feet and rim toward micelle localization. These variables
should afford future opportunities in both the types of hosts
and their respective guests that are amenable to migration into
a variety of both synthetic and natural membranes. Additionally,
the ability to incorporate aromatic groups at the cavitand rim
should allow us to fluorescently label the host and perhaps
further expand upon the types of suitable handles we can
employ.
The transport of sensitive small molecules across biological
membranes has been a long-standing goal of medicinal chem-
istry. Conceptually, several researchers have envisioned encap-
sulating drugs in larger chemical frameworks or capsules to
effect targeted transport to a specific location.34,35 These small
molecule cavitand hosts are themselves guests within the
hydrophobic interior of the micelle and are simple biomimetic
receptors. The next steps of this research program will be to
transport fluorophores and drug-like molecules into more
complicated vesicular and lipid-bilayer systems.
1
vacuum to give 1 as a pale yellow powder (175 mg, 69%). H NMR
(600 MHz, DMSO-d6): δ 0.93 (t, J ) 7.2 Hz, 12H); 2.39 (qn, J ) 7.2
Hz, 8 H); 5.44 (t, J ) 7.8 Hz, 4H); 7.69 (s, 4H); 8.02 (s, 4H); 8.25 (s,
8H); 8.51 (br s, 4H), ESIHRMS m/z: calcd for C64H49N8O8 (M + H)
1057.3668; found 1057.3658.
Representative Procedure for the Synthesis of Cavitands 5 and
8. C11 Ester Cavitand 5. To an oven-dried, 25 mL round-bottomed
flask equipped with a magnetic stirrer and water-cooled condenser were
added C11H23-footed octaamine cavitand, HCl salt24 (100 mg, 0.060
mmol), ethyl 3-ethoxy-3-iminopropanoate hydrochloride39 (0.36 mmol,
70 mg), and anhydrous ethanol (10 mL). The mixture was placed under
argon and heated to reflux for 14 h. The solvent was removed by rotary
evaporation, and the resulting solid was suspended in dry MeOH (25
mL). The suspension was filtered and washed with dry MeOH (3 ×
20 mL) and then dried under high vacuum to yield cavitand 1a (60
mg, 57%) as an off-white solid. 1H NMR (600 MHz, CDCl3/D2O): δ
0.90 (t, J ) 6.6 Hz, 12H); 1.2 - 1.4 (m, 16H); 1.31 (t, J ) 6.6 Hz,
12H); 1.43 (qn, J ) 6.6 Hz, 8H); 2.25 (q, J ) 7.8 Hz, 8H); 4.26 (q, J
) 7.2 Hz, 8H); 4.30 (s, 8H); 5.73 (t, J ) 7.8 Hz, 4H); 7.25 (s, 4H);
7.44 (s, 4H); 8.01 (s, 8H); ESIHRMS m/z: calcd for C116H145N8O16
(M + H+) 1906.0773; found 1906.0739.
C11 p-Nitrobenzylcavitand 8. Cavitand 8 was synthesized on a 0.06
mmol scale according to the procedure used for 5, employing ethyl
2-(4-nitrophenyl)acetimidate hydrochloride S1 (Supporting Informa-
tion), giving an off-white solid (109 mg, 86%). H NMR (600 MHz,
Experimental Section
1. General Information. 1H and DOSY30 NMR spectra were
recorded on a Bruker DRX-600 spectrometer with a 5 mm QNP probe.
Proton chemical shifts are reported in parts per million (δ) with respect
to tetramethylsilane (TMS, δ ) 0) and referenced internally with respect
to the protio solvent impurity. The DOSY spectra were acquired using
an LED pulse sequence with bipolar gradient pulses and two spoil
gradients, as supplied with the Bruker software.36 Sine-shaped pulsed
gradients were incremented from 2.7 to 51.4 G cm-1 with an Acustar
gradient system in 32 steps, with each step consisting of 256 scans.
The raw data was processed using the MestreC program (Mestrelab
Research, Santiago de Compostela). Deuterated NMR solvents were
obtained from Cambridge Isotope Laboratories, Inc., Andover, MA,
and used without further purification. Anhydrous solvents and reagents
were obtained from Aldrich Chemical Co., St. Louis, MO, and were
used as received. Cavitands 4,32 6,37 7,5 and 96 were synthesized
according to reported procedures. All micelle experiments were
conducted by sonication of the indicated amounts of host, guest, and
PC in D2O for 10 min prior to NMR acquisition.
1
THF-d8/D2O 4:1): δ 0.84 (t, J ) 7.2 Hz, 12H); 1.2 - 1.4 (m, 16H);
1.41 (qn, J ) 7.2 Hz, 8H); 2.23 (q, J ) 7.2 Hz, 8H); 4.11 (s, 8H); 5.73
(t, J ) 7.2 Hz, 4H); 7.29 (s, 4H); 7.48 (d, J ) 7.8 Hz, 8H); 7.71 (s,
4H); 7.87 (s, 8H); 8.05 (d, J ) 7.8 Hz, 8H); ESIHRMS m/z: calcd for
C
128H141N12O16 (M + H+) 2102.0582; found 2102.0565.
Acknowledgment. We are grateful to the Skaggs Institute
and the National Institutes of Health (GM 50174) for financial
support. M.P.S. and R.J.H. are Skaggs Postdoctoral fellows. We
wish to thank Dr. Enrique Mann for compound 3.
Supporting Information Available: 1H NMR spectra for all
new cavitands. All spectra for encapsulation results that were
discussed but not illustrated in the text. DOSY results for 1
with adamantylamine in DPC micelles showing one assembly
along with DCl titration data of 1 in THF:D2O. This material
2. Synthesis of New Compounds. Procedure for the Synthesis of
Cavitand 1. Ethyl-footed cavitand 1 was prepared following related
JA0723378
(34) Langer, R. Science 1990, 249, 1527-33.
(38) Amrhein, P.; Shivanyuk, A.; Johnson, D. W.; Rebek, J. J. Am. Chem. Soc.
2002, 124, 10349-10358.
(39) Church, T. J.; Cutshall, N. S.; Gangloff, A. R.; Jenkins, T. E.; Linsell, M.;
S.; Litvak, J.; Rice, K. D.; Spencer, J. R.; Wang, V. R. (Axys Pharma-
ceuticals Corp.) PCT Int. Appl. WO 97-US21849, 1998, p 108.
(35) Langer, R. Acc. Chem. Res. 1993, 26, 537-542.
(36) Wu, D. H.; Chen, A. D.; Johnson, C. S. J. Magn. Reson., Ser. A 1995,
115, 260-264.
(37) Hooley, R. J.; Rebek, J. Org. Lett. 2007, 9, 1179-1182.
9
J. AM. CHEM. SOC. VOL. 129, NO. 31, 2007 9779